ID

36677

Description

Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).; ODM derived from: https://clinicaltrials.gov/show/NCT02453282

Link

https://clinicaltrials.gov/show/NCT02453282

Keywords

Versions (1)
  1. 5/31/19 5/31/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

May 31, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-Small-Cell Lung Carcinoma (NSCLC) NCT02453282

English

Eligibility Non-Small-Cell Lung Carcinoma (NSCLC) NCT02453282

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
for inclusion in the study, patients should fulfill the following criteria:
Description

Criteria Fulfill

Data type

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
aged at least 18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
documented evidence of stage iv nsclc
Description

Non-Small Cell Lung Carcinoma TNM clinical staging

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C3258246
no activating egfr mutation or alk rearrangement
Description

Activating EGFR Gene Mutation Negative | ALK Gene Rearrangement Negative

Data type

boolean

Alias
UMLS CUI [1]
C4525184
UMLS CUI [2]
C4525178
no prior chemotherapy or any other systemic therapy for recurrent/metastatic nsclc
Description

Prior Chemotherapy Absent Non-small cell lung cancer recurrent | Systemic therapy Absent Non-small cell lung cancer recurrent | Prior Chemotherapy Absent Non-small cell lung cancer metastatic | Systemic therapy Absent Non-small cell lung cancer metastatic

Data type

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C0278517
UMLS CUI [2,1]
C1515119
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C0278517
UMLS CUI [3,1]
C1514457
UMLS CUI [3,2]
C0332197
UMLS CUI [3,3]
C0278987
UMLS CUI [4,1]
C1515119
UMLS CUI [4,2]
C0332197
UMLS CUI [4,3]
C0278987
world health organization (who) performance status of 0 or 1
Description

WHO performance status scale

Data type

boolean

Alias
UMLS CUI [1]
C1298650
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients should not enter the study if any of the following exclusion criteria are fulfilled:
Description

Exclusion Criteria Fulfill

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1550543
mixed small-cell lung cancer and nsclc histology or not otherwise specified (nsclc nos)
Description

Small cell carcinoma of lung NSCLC Mixed | NSCLC Not Otherwise Specified

Data type

boolean

Alias
UMLS CUI [1,1]
C0149925
UMLS CUI [1,2]
C0007131
UMLS CUI [1,3]
C0205430
UMLS CUI [2,1]
C0007131
UMLS CUI [2,2]
C1518425
brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)
Description

Metastatic malignant neoplasm to brain | Compression of spinal cord | Exception Metastatic malignant neoplasm to brain Asymptomatic | Exception Compression of spinal cord Asymptomatic | Exception Metastatic malignant neoplasm to brain Treated Stable | Exception Compression of spinal cord Treated Stable | Exception Steroids Redundant

Data type

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2]
C0037926
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0220650
UMLS CUI [3,3]
C0231221
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0037926
UMLS CUI [4,3]
C0231221
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0220650
UMLS CUI [5,3]
C1522326
UMLS CUI [5,4]
C0205360
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0037926
UMLS CUI [6,3]
C1522326
UMLS CUI [6,4]
C0205360
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0038317
UMLS CUI [7,3]
C1313915
prior exposure to immunomodulatory therapy (imt), including, but not limited to, other anti-cytotoxic t-lymphocyte-associated antigen 4 (ctla-4), anti-programmed cell death1 (pd-1), anti-programmed cell death ligand 1 (pd-l1), or anti pd-l2 antibodies, excluding therapeutic anticancer vaccines
Description

Immunomodulation | Anti-CTLA-4 Monoclonal Antibody | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | Exception Vaccine Cancer treatment

Data type

boolean

Alias
UMLS CUI [1]
C1963758
UMLS CUI [2]
C4289973
UMLS CUI [3]
C4289970
UMLS CUI [4]
C4289971
UMLS CUI [5,1]
C1705357
UMLS CUI [5,2]
C0003250
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0042210
UMLS CUI [6,3]
C0920425
active or prior documented inflammatory bowel disease (eg, crohn's disease, ulcerative colitis)
Description

Inflammatory Bowel Disease | Crohn Disease | Ulcerative Colitis

Data type

boolean

Alias
UMLS CUI [1]
C0021390
UMLS CUI [2]
C0010346
UMLS CUI [3]
C0009324
Back to the top of the page

Similar models

Eligibility Non-Small-Cell Lung Carcinoma (NSCLC) NCT02453282

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Criteria Fulfill
Item
for inclusion in the study, patients should fulfill the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Age
Item
aged at least 18 years
boolean
C0001779 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma TNM clinical staging
Item
documented evidence of stage iv nsclc
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Activating EGFR Gene Mutation Negative | ALK Gene Rearrangement Negative
Item
no activating egfr mutation or alk rearrangement
boolean
C4525184 (UMLS CUI [1])
C4525178 (UMLS CUI [2])
Prior Chemotherapy Absent Non-small cell lung cancer recurrent | Systemic therapy Absent Non-small cell lung cancer recurrent | Prior Chemotherapy Absent Non-small cell lung cancer metastatic | Systemic therapy Absent Non-small cell lung cancer metastatic
Item
no prior chemotherapy or any other systemic therapy for recurrent/metastatic nsclc
boolean
C1514457 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0278517 (UMLS CUI [1,3])
C1515119 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0278517 (UMLS CUI [2,3])
C1514457 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0278987 (UMLS CUI [3,3])
C1515119 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0278987 (UMLS CUI [4,3])
WHO performance status scale
Item
world health organization (who) performance status of 0 or 1
boolean
C1298650 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Exclusion Criteria Fulfill
Item
patients should not enter the study if any of the following exclusion criteria are fulfilled:
boolean
C0680251 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Small cell carcinoma of lung NSCLC Mixed | NSCLC Not Otherwise Specified
Item
mixed small-cell lung cancer and nsclc histology or not otherwise specified (nsclc nos)
boolean
C0149925 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C0205430 (UMLS CUI [1,3])
C0007131 (UMLS CUI [2,1])
C1518425 (UMLS CUI [2,2])
Metastatic malignant neoplasm to brain | Compression of spinal cord | Exception Metastatic malignant neoplasm to brain Asymptomatic | Exception Compression of spinal cord Asymptomatic | Exception Metastatic malignant neoplasm to brain Treated Stable | Exception Compression of spinal cord Treated Stable | Exception Steroids Redundant
Item
brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)
boolean
C0220650 (UMLS CUI [1])
C0037926 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0220650 (UMLS CUI [3,2])
C0231221 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0037926 (UMLS CUI [4,2])
C0231221 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0220650 (UMLS CUI [5,2])
C1522326 (UMLS CUI [5,3])
C0205360 (UMLS CUI [5,4])
C1705847 (UMLS CUI [6,1])
C0037926 (UMLS CUI [6,2])
C1522326 (UMLS CUI [6,3])
C0205360 (UMLS CUI [6,4])
C1705847 (UMLS CUI [7,1])
C0038317 (UMLS CUI [7,2])
C1313915 (UMLS CUI [7,3])
Immunomodulation | Anti-CTLA-4 Monoclonal Antibody | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | Exception Vaccine Cancer treatment
Item
prior exposure to immunomodulatory therapy (imt), including, but not limited to, other anti-cytotoxic t-lymphocyte-associated antigen 4 (ctla-4), anti-programmed cell death1 (pd-1), anti-programmed cell death ligand 1 (pd-l1), or anti pd-l2 antibodies, excluding therapeutic anticancer vaccines
boolean
C1963758 (UMLS CUI [1])
C4289973 (UMLS CUI [2])
C4289970 (UMLS CUI [3])
C4289971 (UMLS CUI [4])
C1705357 (UMLS CUI [5,1])
C0003250 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0042210 (UMLS CUI [6,2])
C0920425 (UMLS CUI [6,3])
Inflammatory Bowel Disease | Crohn Disease | Ulcerative Colitis
Item
active or prior documented inflammatory bowel disease (eg, crohn's disease, ulcerative colitis)
boolean
C0021390 (UMLS CUI [1])
C0010346 (UMLS CUI [2])
C0009324 (UMLS CUI [3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial